Objective: We previously reported that the nonpeptide tachykinin NK 2 receptor antagonist SR48968 (saredutant) significantly inhibits neurokinin A-induced bronchoconstriction in patients with asthma. MEN11420 (nepadutant) is a bicyclic peptide tachykinin NK 2 receptor antagonist. The aim of the trial was to examine the effect of nepadutant on neurokinin Ainduced bronchoconstriction in man. Methods: 12 patients with stable, mild to moderate asthma participated in a double-blind, placebo-controlled crossover trial and received, with intervals of 1 week, MEN11420 2 mg, MEN11420 8 mg and placebo (i.v.). Increasing concentrations of NKA (10 À9 to 10 À6 moles/ml) were inhaled immediately after (d1) and 24 hours after (d2) administration of treatment. Results: On d1 both MEN11420 2 and 8 mg shifted the dose response curve for neurokinin A to the right (log PC 20 FEV 1 neurokinin A [moles/ml]; mean± SEM À6.38±0.26 after 2 mg, À6.11±0.23 after 8 mg, versus À6.95±0.27 after placebo]. On d2 MEN11420 had no effect on neurokinin A-induced bronchoconstriction. Conclusion: In conclusion, the tachykinin NK 2 receptor antagonist nepadutant significantly inhibits bronchoconstriction induced by neurokinin A in patients with asthma.
Introduction
The tachykinins substance P and neurokinin A are localized in sensory airway nerves and immune cells. They have been recovered from human airways and can be released by several stimuli, including allergen, ozone and inflammatory mediators. In asthmatic airways they can contribute to smooth muscle contraction, submucosal gland secretion, vasodilatation, an increase in vascular permeability, stimulation of cholinergic nerves and stimulation of immune cells Substance P and neurokinin A contract human airways in vitro and in vivo, neurokinin A being more potent than substance P and asthmatic patients being more sensitive than normal subjects [Joos et al.1987] . The airway effects of tachykinins are mediated by tachykinin NK 1 , NK 2 and NK 3 receptors Maggi, 1993] . In vitro studies have revealed that neurokinin A contracts airway smooth muscle directly, by stimulation of tachykinin NK 2 receptors [Advenier et al. 1992] . Tachykinin-induced bronchoconstriction is predominantly mediated by tachykinin NK 2 receptors, but tachykinin NK 1 receptors are also involved [Amadesi et al. 2001; Naline et al. 1996 ].
We previously reported that the nonpeptide tachykinin NK 2 receptor antagonist SR 48968 (saredutant) was able to partially inhibit neurokinin A-induced bronchoconstriction in patients with asthma [Van Schoor et al. 1998 ]. MEN11420 (nepadutant) competitively binds with high affinity (K I ¼ 2.5 nM) and specificity to the human NK 2 receptor [Catalioto et al. 1998 ]. In in vivo animal models, MEN11420 produces an effective and long-lasting blockade of the NK 2 receptors expressed in the smooth muscle of the intestinal, genitourinary tract and respiratory tract [Tramontana et al. 1998 ]. The aim of the present study was to evaluate the effect of MEN11420 on the bronchoconstriction induced by inhaled neurokinin A in a group of patients with mild to moderate asthma.
Methods

Patients
Twelve male and female, adult non-smoking subjects with stable mild-to-moderate asthma were recruited for the trial. All participants met the Global Initiative for Asthma diagnostic criteria for asthma (www.ginasthma.com) . No relevant concomitant diseases were present. All patients were atopic. No concomitant therapy, including nonprescription drugs, was allowed starting from 7 days prior to the treatment phase of the trial. Drugs for asthma had to be discontinued for at least 8 hours before each study visit. Inhaled steroids could be continued, but no change in dose was allowed during the whole duration of the trial. Their morning baseline forced expiratory volume in 1 second (FEV 1 ) was >70% of predicted and the provocative concentration of methacholine causing a 20% fall in FEV 1 (PC 20 FEV 1 ) was 8 mg ml À1 . The PC 20 FEV 1 of neurokinin A was 3.3 10 À7 moles ml À1 . No patient was studied within 4 weeks of an upper respiratory tract infection or exacerbation of asthma. The ethical committee of the Ghent University Hospital approved the study protocol. All participants gave their written informed consent.
Study design
This study was of a randomized, double-blind, placebo-controlled, three period and crossover design. On the screening day, the patients underwent an inhalational challenge with methacholine and neurokinin A. The screening tests had to be performed within 1 to 3 weeks prior to the start of the study. Each study period (three in total) lasted about 25 hours and the patients were allowed to pass the night at home. The patients arrived at the department at 8 am on each study day. An electrocardiogram (ECG) and blood samples were taken before each experimental period.
The study medication consisted of 2 mg or 8 mg of MEN11420 (c{[(beta-D-GlcNac)Asn-Asp-Trp-Phe-Dpr-Leu]c(2 beta-5 beta)}) or matched placebo (saline solution). Twenty millilitres of the drug or placebo solution was given intravenously over 10 minutes. A bronchial challenge with neurokinin A was performed immediately after and 24 hours after administration of the trial medication. The baseline FEV 1 before each challenge had to be within 10% of the baseline FEV 1 , obtained at the screening visit; if this was not the case, the patient was rescheduled for another visit. The patients fasted overnight and had no alcohol (within 48 hours), no caffeine containing foods or drinks (within 24 hours). They were not allowed to participate in unaccustomed, strenuous exercise within 72 hours before each study visit. Short-acting ß 2 -agonists were withheld for at least 8 hours before each neurokinin A challenge. During the experimental period supine blood pressure and heart rate were evaluated every 15 minutes. After the first neurokinin A challenge the patients left the study centre, and the next morning they performed the second, 24 hours postdose neurokinin A challenge. Study periods 2 and 3 were identical to study period 1 and were performed with intervals of 7 days.
Pulmonary function testing
The FEV 1 was measured using a water-sealed spirometer (Pulmonet III, Sensor Medics, Bilthoven, The Netherlands). The value that we used was the highest of three consecutive manoeuvres. All manoeuvres were performed with the patient in sitting position, the nose occluded by a clip. The same lung function technician and spirometer were used throughout the study.
Bronchial challenge tests
The PC 20 for methacholine was determined by measuring the decrease in FEV 1 after inhalation of doubling concentration of methacholine, starting with a 1 mg/ml solution, according to the method of Cockcroft et al. [1977] . Methacholine solutions were freshly prepared and nebulised with a Wiesbadener Doppel inhalator (Wiesbadener Inhalatoren-Vertrieb, Wiesbaden, Germany). Neurokinin A was inhaled as previously described [Van Schoor et al. 1998 ]. Before each neurokinin A inhalation baseline FEV 1 was determined. The patients then inhaled the neurokinin A diluent and FEV 1 was measured after 3 and 7 minutes after the start of inhalation, with the lowest value of each considered as the postdiluent baseline FEV 1 . The actual neurokinin A challenge was performed, provided the FEV 1 did not fall by >10% after inhaling diluent. During the challenge increasing concentrations of neurokinin A (3.3 Â 10 À9 , 1.0 Â 10 À8 , 3.3 Â 10 À8 , 1.0 Â 10 À7 , 3.3 Â 10 À7 , 1.0 Â 10 À6 mol ml À1 ) were inhaled until FEV 1 fell by at least 20% of the postdiluent baseline value.
Neurokinin A was obtained from Peninsula (St Helens, UK) and was diluted in saline containing 1% human serum albumin (Behringwerke, Marburg, Germany). The dilutions of neurokinin A were prepared on the morning of the challenge and kept on ice until nebulization. The aerosols were produced using a Mallinckrodt jet nebulizer and sprayed in a 30 l collapsible bag [Cheung et al. 1992 ]. This bag served as a drying chamber and was filled with nitrogen (N 2 ) gas. Then 0.5 ml of diluent or each subsequent neurokinin A concentration was sprayed by compressed N 2 (400 kPa) in 60±10s into the drying chamber, in which the droplets evaporated rapidly to dry particles. Finally, the patient inhaled the aerosol from the bag in 2 minutes by quiet tidal breathing trough a three-way valve and a mouthpiece, until the bag collapsed. Supplementary oxygen (at a flow rate of 4 l min À1 , inspiratory oxygen fraction, FIO 2, 0.995) was supplied into the mouthpiece. The patient performed the inhalation in the sitting position, with the nose occluded by a clip. FEV 1 was measured 3 and 7 minutes after the start of inhalation. The nebulizations of the different concentrations were initiated at 10 minutes intervals. The neurokinin A challenge was stopped once the FEV 1 decreased by 20% or more. This allowed calculating the PC 20 FEV 1 using a semi-logarithmic concentration-response curve. A PC 20 value of 3.3 Â 10 À6 mol ml À1 was attributed arbitrarily in those cases where the desired fall in FEV 1 was not obtained.
Pharmacokinetics
Blood samples for the quantification of MEN11420 plasma concentrations were taken predose, immediately after the infusion, at the end of the neurokinin A challenge and at the 24 hours post MEN11420/placebo infusion visit. Samples (7 ml) were taken from a cannula and collected in a lithium heparin tube. Within 1 hour of collection the samples were centrifuged at 3000 rpm at 4 C for 10 min. The plasma was then decanted as two equal aliquots into separate plastic tubes and was stored at -20 C. The samples were analysed by HPLC MS/MS at Menarini Ricerche, Department of Pharmacokinetics and Drug Metabolism, Rome, Italy.
Statistical analysis
Comparisons of the predose baseline FEV 1 values between the three study days and of the postdiluent baseline FEV 1 values between the three study days were performed using a crossover analysis of variance (ANOVA).
The values of PC 20 FEV 1 NKA (expressed in mol ml À1 ) were log 10 transformed; treatment with MEN11420 was compared with placebo, at 1.5 hours and 24 hours postdose, by means of an ANOVA test. A p-value of 0.05 was considered significant. Data are expressed as the mean ± SEM of the logarithmically transformed values. Comparisons of the plasma concentrations after administration of the different doses of MEN11420 were performed using a Wilcoxon matched pair test.
Results
Patients
Twelve patients, aged 2055 years (mean 32.3 years), participated in the trial. No patients were taking inhaled steroids. Their mean (±SEM) baseline FEV 1 was 3.70±0.26 l or 91.3±3.07% of predicted. Their mean PC 20 FEV 1 methacholine was 4.6±0.39 mg ml À1 , and their mean PC 20 FEV 1 neurokinin A was 8.31 Â 10 À8 ±2.40 Â 10 À8 moles ml À1 (Table 1) .
Effects of MEN11420 on baseline FEV 1
There was no statistically significant difference between the baseline 1 (¼prechallenge) and baseline 2 (¼postdiluent) mean FEV 1 (±SEM) values on the treatment (MEN11420 2 mg and MEN11420 8 mg) (3.59±0.27 L and 3.68±0.25 L, 3.57±0.29 L and 3.60±0.26 L) and the placebo day (3.66±0.64 L and 3.60±0.26 L) immediately postdose. 
Reproducibility of the neurokinin A challenge
At screening, all 12 subjects responded to NKA inhalation and the mean±SEM log 10 PC 20 FEV 1 NKA was À7.32±0.15. After placebo, the mean±SEM log 10 PC 20 FEV 1 NKA was À6.96±0.27 and À6.89±0.31 at 1.5 and 24 hours postdose, respectively (NS). The mean 'maximal' percentage fall in FEV 1 after inhalation of NKA at which a fall in FEV 1 ! 20% was reached, was À28.75%±1.35 at screening and À24.97%±2.94 and 23.78±3.41 at 1.5 and 24 hours postdose respectively postplacebo (NS).
Effect of MEN11420 on neurokinin A-induced bronchoconstriction
The shift in doseresponse curve for neurokinin A was nearly significant at a dose of 2 mg. A significant shift of the doseresponse curve was seen for 8 mg.
After placebo log 10 PC 20 FEV 1 NKA±SEM was À6.96±0.28 after 2 mg MEN11420 À6.38±0.26 (p > 0.05), after 8 mg À6.11±0.24 (p ¼ 0.028). The individual doseresponse curves to inhaled neurokinin A on the first study day are depicted in Figure 2 . At day 2 (24 hours after administration) no significant effect was seen. After placebo log 10 PC 20 FEV 1 NKA±SEM was À6.89±0.0. After 2 mg MEN11420 À7.15±0.27 (p > 0.05), after 8 mg À6.96±0.25 (p > 0.05).
Plasma concentrations of MEN11420
MEN11420 plasma concentrations showed a 95% (2 mg) to 87% (8 mg) fall in concentration in a time-period of 6090 minutes. After 24 hours MEN11420 was no longer detectable in most samples. There was a significant difference in plasma concentrations between the 2 mg dose and 8 mg dose (Table 2) .
Drug safety MEN11420 was biologically and clinically well tolerated. No serious adverse events were noted.
Discussion
In this study, the tachykinin NK 2 receptor antagonist MEN11420 (nepadutant) was found to inhibit bronchoconstriction induced by inhaled neurokinin A. The activity of this bicyclic peptide compound was observed at two doses (2 and 8 mg, given intravenously) and was similar to what we observed with the nonpeptide tachykinin NK 2 receptor antagonist SR48968 (saredutant) [Van Schoor et al. 1998 ].
Tachykinins are potent contractors of airways. Substance P (SP) and neurokinin A (NKA) induce bronchoconstriction in humans, with asthmatics being more sensitive than normal subjects [Joos et al. 1987] . In vitro studies on isolated human bronchi and bronchioli have reported that tachykinin NK 2 receptors are present on smooth muscle of both large and small airways and mediate part of the bronchoconstrictor effect of tachykinins [Advenier et al. 1992 ]. In small-and medium-sized airways NK 1 receptors are also present and mediate a transient, lowintensity contraction [Amadesi et al. 2001; Naline et al. 1996 ].
The tachykinin NK2 receptor antagonist, MEN11420, 8 mg given intravenously, was previously found to inhibit neurokinin A-stimulated gastrointestinal motility in human [Lö rdal et al. 2001] . In patients with asthma the potent nonpeptide tachykinin NK 2 receptor antagonist SR48968 (saredutant) causes a significant inhibition of neurokinin A-induced bronchoconstriction, with a 35-fold shift of the doseresponse curve for NKA to the right. In this study similar observations were found with MEN11420 (nepadutant), a chemically unrelated tachykinin NK2 receptor antagonist. While baseline lung function was not affected, we observed a significant protective effect against neurokinin A 1.5 hours postdose. This protective effect was no longer seen 24 hours postdose.
It has long been thought that only NK 2 receptors are involved in contraction of isolated human airways [Advenier et al. 1992] . However in small-diameter bronchi ($1 mm in diameter), in addition to a robust NK 2 tachykinin receptormediated contraction, tachykinins also cause contraction via NK 1 receptor stimulation. The NK 1 -mediated contraction of small bronchi appears to be mediated by prostanoids [Naline et al. 1996] . Pretreatment with interleukin-1b potentiates the contraction of these small human bronchi to a specific NK 1 receptor agonist [Barchasz et al. 1999] . In an extensive study on medium-sized human isolated bronchi (25 mm in diameter) the specific NK 1 receptor agonist [Sar 9 , Met(O 2 ) 11 ] SP was found to induce contraction in about 60% of the preparations, an effect which was not mediated by prostanoids, but from a direct activation of smooth muscle receptors and release of inositol phosphate [Amadesi et al. 2001] . So, it appears that in both small-and medium-sized human bronchi part of the contraction induced by tachykinins is mediated by tachykinin NK 1 receptors. Although NK 2 receptors mediate most of the direct smooth muscle contracting effect of NKA [Naline et al. 1996 ], recent trials have proved that there is also a contribution of NK 1 and NK 3 receptors.
DNK 333, a dual NK 1 /NK 2 receptor antagonist, showed a bronchoprotective effect against inhaled NKA at 1 hour postdose but not at 10 hours postdose. The patient group evaluated in both trials were similar and the study methodology was equal, yet the protective effect on the bronchoconstrictor effect of inhaled neurokinin A Patient 1 1.5h post-dose 10 -10 10 -9 10 -8 10 -7 10 -6 10 -10 10 -9 10 -8 10 -7 10 -6 10 -5 Conc NKA 10 -10 10 -9 10 -8 10 -7 10 -6 10 -5 10 -10 10 -9 10 -8 10 -7 10 -6 10 -5 10 -10 10 -9 10 -8 10 -7 10 -6 10 -10 10 -9 10 -8 10 -7 10 -6 10 -5 Conc NKA 10 -10 10 -9 10 -8 10 -6 10 -7 10 -5 Δ FEV 1 (%) 10 -10 10 -9 10 -8 10 -7 10 -6
10 -10 10 -9 10 -8 10 -6 10 -7 10 -5 10 -10 10 -9 10 -8 10 -6 10 -7 10 -5 10 -10 10 -9 10 -8 10 -6 10 -7 10 -10 10 -9 10 -8 10 -6 10 -7 10 -5 was higher in the DNK 333 trial. The shift in the concentration response curve for neurokinin A was 35 in this study, whereas in the DNK333 study a shift of at least 1620 was observed [Joos et al. 2004 ]. CS-003, the first triple tachykinin receptor antagonist, has shown a bronchoprotective effect at 1 and 8 hours postdose, whereas the protective effect of DNK333 was shown at 1 hour postdose (protection in 15 out of 18 patients) but not at 10 hours postdose. Five out of sixteen patients showed complete protection at 1 and 8 hours postdose, respectively, for NKA even with the highest NKA challenge dose [Schelfhout et al. 2006 ]. It seems that blocking the three receptors offers the best protection against NKA-induced bronchoconstriction. To demonstrate the contribution of each neurokinin receptor antagonist separately we need to block all receptors with selective antagonists. Also a comparison between MEN11420 and the dual or triple neurokinin antagonists in the same population and same setting could help us.
Plasma concentrations decreased very fast postdose. After 24 hours the drug was no longer detectable in most of the patients. This can explain why no bronchoprotective effect was seen at 24 hours postdose. Also when the drug still had a bronchoprotective effect, the plasma concentrations were very low; this can be explained by the high affinity to the receptors that is, plasma kinetics did not correlate with the kinetics at receptor level.
Recently, MEN15596, a new orally active tachykinin NK2 receptor antagonist was synthesized as a back up of the bicyclic hexapeptide antagonist, nepadutant. In comparison with the pseudopeptide nepadutant it has a lower molecular weight, higher potency and selectivity in blocking the human tachykinin NK2 receptor. This feature renders MEN15596 a potential new drug for the therapy of chronic gastrointestinal disorders, such as irritable bowel syndrome, or asthma where the role of tachykinin NK2 receptors have been demonstrated [Meini et al. 2009; Cialdai et al. 2006 ]. In conclusion, we have demonstrated that MEN11420 is able to block NKA induced bronchoconstriction in asthmatic patients. This drug was well tolerated and showed no drug-related adverse events.
